While mRNA vaccines have received intense attention of late, another class of nucleic acid therapeutics has been growing steadily in recent years. Its impact could be equally profound. Nucleic acid ...

Myotonic dystrophy type 1 currently has no approved therapies. New research on the safety of delpacibart etedesiran ― an antibody–oligonucleotide conjugate developed to treat the underlying cause of ...

The authors report a phase 1–2 trial of del-desiran, an antibody–oligonucleotide conjugate designed to reduce DMPK mRNA, to treat myotonic dystrophy type 1.

Collaboration of scientists from the University of Utah and Vanderbilt University looks to gain insights for the diagnosis of multiple sclerosis (ms) and autism. with the Breaking Science News daily ...